HC Wainwright Cuts Earnings Estimates for Benitec Biopharma

Key Points

• HC Wainwright lowered its Q1 2027 EPS estimate for Benitec Biopharma to $0.29 per share loss from $0.28, while maintaining a “Buy” rating. The firm projects a $1.34 per-share loss for full-year 2027.
• Benitec reported quarterly EPS of $0.26 per share loss, in line with consensus estimates. The stock opened at $9.75, down 2.7%, near its 12-month low of $9.26.
• Analyst sentiment remains broadly positive, with a “Moderate Buy” consensus rating and an average price target of $24.00; institutional investors own 52.19% of the company.

Benitec Biopharma Limited (NASDAQ:BNTC - Free Report) - Research analysts at HC Wainwright reduced their Q1 2027 earnings per share (EPS) estimates for Benitec Biopharma in a report released on Monday, September 28th. HC Wainwright analyst R. Selvaraju now forecasts that the biotechnology company will post earnings per share of ($0.29) for the quarter, down from their prior estimate of ($0.28). HC Wainwright currently has a "Buy" rating on the stock. The consensus estimate for Benitec Biopharma's current full-year earnings is ($1.29) per share. HC Wainwright also issued estimates for Benitec Biopharma's Q2 2027 earnings at ($0.32) EPS, Q3 2027 earnings at ($0.35) EPS, Q4 2027 earnings at ($0.38) EPS and FY2027 earnings at ($1.34) EPS.

Benitec Biopharma (NASDAQ:BNTC - Get Free Report) last posted its quarterly earnings data on Monday, September 14th. The biotechnology company reported ($0.26) earnings per share for the quarter, meeting the consensus estimate of ($0.26).

A number of other research firms have also weighed in on BNTC. Wall Street Zen lowered Benitec Biopharma from a "hold" rating to a "sell" rating in a research note on Saturday, September 19th. Citigroup reaffirmed a "market outperform" rating on shares of Benitec Biopharma in a research note on Tuesday, September 15th. Royal Bank Of Canada upgraded Benitec Biopharma to an "outperform" rating in a research report on Tuesday, September 15th. Guggenheim lowered Benitec Biopharma from a "buy" rating to a "neutral" rating in a research note on Wednesday, June 10th. Finally, Wedbush raised their target price on shares of Benitec Biopharma from $16.00 to $17.00 and gave the stock an "outperform" rating in a report on Tuesday, September 15th. Seven analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, the stock presently has a consensus rating of "Moderate Buy" and an average target price of $24.00.

Benitec Biopharma Stock Down 2.7%

Benitec Biopharma stock opened at $9.75 on Wednesday. The firm has a fifty day simple moving average of $12.08 and a two-hundred day simple moving average of $11.97. Benitec Biopharma has a twelve month low of $9.26 and a twelve month high of $16.76. The company has a market capitalization of $340.11 million, a PE ratio of -9.95 and a beta of 0.27.

Hedge Funds Weigh In On Benitec Biopharma

Hedge funds and other institutional investors have recently made changes to their positions in the business. Simplify Asset Management Inc. increased its position in Benitec Biopharma by 271.9% during the 1st quarter. Simplify Asset Management Inc. now owns 562,242 shares of the biotechnology company's stock valued at $5,988,000 after purchasing an additional 411,079 shares during the period. MYDA Advisors LLC grew its holdings in shares of Benitec Biopharma by 221.4% during the 4th quarter. MYDA Advisors LLC now owns 225,000 shares of the biotechnology company's stock worth $3,031,000 after acquiring an additional 155,000 shares during the period. AWM Investment Company Inc. bought a new position in shares of Benitec Biopharma in the 2nd quarter worth approximately $2,515,000. Bank of New York Mellon Corp purchased a new position in shares of Benitec Biopharma in the 2nd quarter valued at approximately $804,000. Finally, Empery Asset Management LP bought a new stake in shares of Benitec Biopharma during the fourth quarter valued at approximately $747,000. Institutional investors own 52.19% of the company's stock.

About Benitec Biopharma

Benitec Biopharma Inc NASDAQ: BNTC is a clinical-stage biotechnology company developing genetic medicines based on DNA-directed RNA interference (ddRNAi). The company's technology is designed to enable long-lasting suppression of disease-causing genes by delivering genetic instructions that produce RNA interference molecules within targeted cells.

Benitec's lead product candidate is BB-301, an investigational gene therapy being developed for oculopharyngeal muscular dystrophy type 1 (OPMD), a rare inherited disorder that can cause progressive weakness of the muscles involved in swallowing and eye movement.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.